



HAL
open science

Identification and functional analyses of CBS alleles in Spanish and Argentinian homocystinuric patients

Monica Cozar, Roser Urreizti, Laura Teixeira Vilarinho, Carola Grosso, Raquel Dodelson de Kremer, Carla G Asteggiano, Jaime Dalmau, Ana Maria Garcia, María Antonia Vilaseca, Daniel Grinberg, et al.

► To cite this version:

Monica Cozar, Roser Urreizti, Laura Teixeira Vilarinho, Carola Grosso, Raquel Dodelson de Kremer, et al.. Identification and functional analyses of CBS alleles in Spanish and Argentinian homocystinuric patients. *Human Mutation*, 2011, 32 (7), pp.835. 10.1002/humu.21514 . hal-00649062

HAL Id: hal-00649062

<https://hal.science/hal-00649062>

Submitted on 7 Dec 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Identification and functional analyses of CBS alleles in Spanish and Argentinian homocystinuric patients

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0637.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	31-Mar-2011
Complete List of Authors:	<p>Cozar, Monica; Universitat de Barcelona, Departament de Genetica; CIBERER; IBUB</p> <p>Urreizti, Roser; Universitat de Barcelona, Departament de Genetica; CIBERER; IBUB</p> <p>VILARINHO, Laura; Medical Genetics Institute, Clinical Biology</p> <p>Grosso, Carola; Universidad Nacional de Córdoba Hospital de Niños, Centro de Estudio de las Metabolopatías Congénitas, CEMECO, Facultad de Ciencias Médicas</p> <p>Dodelson de Kremer, Raquel; Universidad Nacional de Córdoba Hospital de Niños, Centro de Estudio de las Metabolopatías Congénitas, CEMECO, Facultad de Ciencias Médicas</p> <p>Asteggiano, Carla; Children's Hospital of Santísima Trinidad, CEMECO</p> <p>Dalmau, Jaime; Hospital Infantil La Fe, Division of Metabolism,</p> <p>Garcia, Ana; Hospital Infantil La Fe, Division of Metabolism,</p> <p>Vilaseca, María; Hospital Sant Joan de Déu, Bioquímica</p> <p>Grinberg, Daniel; Universitat de Barcelona, Departament de Genetica; CIBERER; IBUB</p> <p>Balcells, Susana; Universitat de Barcelona, Departament de Genetica; CIBERER; IBUB</p>
Key Words:	CBS mutations, homocystinuria, Southern blot, mini-gene, heterologous expression, enzyme activity

SCHOLARONE™
Manuscripts

1
2
3
4 **Identification And Functional Analyses of CBS Alleles In Spanish And**
5
6 **Argentinian Homocystinuric Patients**
7

8
9 Mónica Cozar,^{1*} Roser Urreizti,^{1*} Laura Vilarinho,² Carola Grosso,³ Raquel Dodelson
10 de Kremer,³ Carla G. Asteggiano,³ Jaime Dalmau,⁴ Ana María García,⁴ María Antonia
11 Vilaseca,⁵ Daniel Grinberg,^{1*} and Susana Balcells^{1*#}
12
13
14
15
16
17

18
19 ¹ Departament de Genètica, Universitat de Barcelona, IBUB, Centro de Investigación
20 Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, Spain
21

22
23
24 ² Instituto de Genética Médica Jacinto Magalhaes, Porto, Portugal
25

26
27 ³ Centro de Estudio de las Metabolopatías Congénitas (CEMECO), Facultad de
28 Ciencias Médicas, Universidad Nacional de Córdoba, Hospital de Niños de la
29 Santísima Trinidad, Córdoba, Argentina.
30
31

32
33
34 ⁴ Unidad de Nutrición y Metabolopatías. Hospital Infantil La Fe, Valencia, Spain.
35

36
37 ⁵ Servei de Bioquímica. Hospital Sant Joan de Déu, Barcelona, Spain.
38
39
40

41
42 * Equal contributors.
43

44 # Correspondence to: Dr. Susana Balcells, Departament de Genètica, Facultat de
45 Biologia, Universitat de Barcelona, Av. Diagonal 645, E-08028, Barcelona, Spain.
46
47

48
49 Email: sbalcells@ub.edu
50

51
52 Tel.: +34 93 403 5418
53

54
55 Fax: +34 93 403 4420
56
57
58
59
60

1
2
3 **ABSTRACT:** Homocystinuria due to CBS deficiency (MIM#236200) is a rare
4
5
6 autosomal recessive disorder characterized by elevated plasma levels of
7
8
9 homocysteine (Hcy) and methionine (Met). Here we present the analysis of 22
10
11 unrelated patients of different geographical origins, mainly Spanish and Argentinian.
12
13
14 Twenty-two different mutations were found, ten of which were novel. Five new
15
16 mutations were missense and five were deletions of different sizes, including a 794-
17
18 bp deletion (c.532-37_736+438del794) detected by Southern blot analysis. To assess
19
20 the pathogenicity of these mutations, seven were expressed heterologously in *E. coli*
21
22 and their enzyme activities were assayed *in vitro*, in the absence and presence of the
23
24 CBS activators PLP and SAM. The presence of the mutant proteins was confirmed by
25
26 Western-blotting. Mutations p.M173del, p.I278S, p.D281N and p.D321V showed null
27
28 activity in all conditions tested, while mutations p.49L, p.P200L and p.A446S retained
29
30 different degrees of activity and response to stimulation. Finally, a minigene strategy
31
32 allowed us to demonstrate the pathogenicity of an 8-bp intronic deletion, which led
33
34 to the skipping of exon 6. In general, frameshifting deletions correlated with a more
35
36 severe phenotype, consistent with the concept that missense mutations may recover
37
38 enzymatic activity under certain conditions.
39
40
41
42
43
44
45
46
47
48

49 **KEY WORDS:** CBS mutations; homocystinuria; Southern blot; mini-gene;
50
51
52 heterologous expression; enzyme activity
53
54
55
56
57
58
59
60

Introduction

Homocysteine (Hcy) is a sulfur-containing amino acid that occupies a major regulatory branch point in methionine metabolism. Homocysteine may be either remethylated to methionine or catabolized to form cysteine through the transsulfuration pathway. The first step of transsulfuration involves the condensation of homocysteine with serine to form cystathionine, a reaction catalyzed by the enzyme cystathionine β -synthase (CBS; EC 4.2.1.22).

Mutations in the CBS gene (MIM# 613381) cause classical homocystinuria (Hcu, MIM# 236200), an autosomal recessive disease characterized by severe hyperhomocysteinemia and homocystinuria, decreased plasma levels of cysteine and, often, hypermethioninemia. At the clinical level, classical homocystinuria mainly affects the eye, the skeleton, the vascular system and the central nervous system (CNS). Symptoms usually include ectopia lentis, osteoporosis, scoliosis, Marfanoid features, premature arteriosclerosis, thromboembolism and mental retardation (Mudd, et al., 1985). Age of onset and disease severity are highly variable, ranging from dramatically affected children to asymptomatic adults (Magner, et al., 2011; Skovby, et al., 2010; Walter, et al., 1998; Yap and Naughten, 1998). Treatments that lower tHcy, such as B-vitamins, dietary methionine restriction, and betaine supplementation, can significantly reduce the incidence of vascular events (the main cause of death in these patients) and improve the neurological problems (Wilcken and Wilcken, 1997; Yap, et al., 2001; Yap and Naughten, 1998).

Homocystinuria is a rare disease with variable incidence. While the worldwide incidence is estimated as 1/344000 born alive (Mudd, et al., 1995), in Qatar it is 1/3124 (El-Said, et al., 2006) and in Japan 1/800 000 (Mudd, et al., 1995). In Northern Europe the incidence may be of 1/20500 to 1/6400, as estimated from the high

1
2
3 number of p.I278T mutation carriers found in some populations (Gaustadnes, et al.,
4
5 1999; Refsum, et al., 2004).
6
7

8 To date, more than 150 different CBS mutations have been found worldwide,
9
10 some of them common. Mutation p.I278T is considered panethnic and is particularly
11
12 frequent in Northern Europe (Janosik, et al., 2001b; Kraus, et al., 1999; Moat, et al.,
13
14 2004). In Ireland, the p.G307S mutation accounts for 71% of the mutant alleles
15
16 (Gallagher, et al., 1995), and in the Iberian Peninsula and Colombia, mutation
17
18 p.T191M represents between 40% and 75% (Urreizti, et al., 2006a) of the mutant
19
20 alleles.
21
22

23
24 A truncated form of the human CBS enzyme lacking the C-terminal regulatory
25
26 domain has been crystallized (Janosik, et al., 2001a; Meier, et al., 2001) and
27
28 structurally characterized (Banerjee and Zou, 2005; Kabil, et al., 2001; Kery, et al.,
29
30 1999; Meier, et al., 2001; Taoka, et al., 2002). The active form of this cytoplasmic
31
32 enzyme is a homotetramer of four 63-KDa subunits. Each subunit combines one
33
34 heme group and one pyridoxal phosphate (PLP), the latter acting as a cofactor in the
35
36 reaction. In addition, each subunit binds the allosteric activator S-Adenosil-
37
38 Methionine (S-AdoMet or SAM), an intermediate in the methionine cycle.
39
40 Heterologous expression in *E. coli* has been widely used to test the functionality of
41
42 the CBS mutant alleles independently from the patient's genetic background (de
43
44 Franchis, et al., 1994; Katsushima, et al., 2006; Maclean, et al., 2002). It has been
45
46 proven to be a useful tool since the *E. coli*-expressed human CBS is indistinguishable
47
48 from that obtained from cultured fibroblasts (Bukovska, et al., 1994; Kozich and
49
50 Kraus, 1992). In addition, *in vitro*, its relative activity in response to PLP and SAM is
51
52 comparable to that of the enzyme obtained from human tissues (Bukovska, et al.,
53
54 1994; Kozich and Kraus, 1992).
55
56
57
58
59
60

1
2
3 This study updates the CBS mutation spectrum of the homocystinuric patients
4 from the Iberian Peninsula by presenting the analysis of 16 new cases. It also includes
5 one Norwegian, one Indian and four Argentinian patients. In this cohort of 22 cases,
6 22 mutations were found, ten of which were novel. The new mutations include a
7 deletion of 794 bp (c.532-37_736+438del794) detected by Southern blot analysis and
8 an intronic deletion that leads to the skipping of exon 6, which was characterized
9 using a minigene strategy. The pathogenic role of seven of the changes was assessed
10 by heterologous expression of these mutant proteins, and their stability and activity
11 were analyzed.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Materials And Methods**

31 **Patients**

32
33
34
35
36 Twenty-six patients with classical homocystinuria from 22 unrelated pedigrees
37 were involved in this study. Patients were initially diagnosed by their physicians on
38 the basis of clinical manifestations suggestive of homozygous CBS deficiency.
39 Biochemically, these patients presented with a combination of severe
40 hyperhomocysteinemia (typically above 150 $\mu\text{mol/l}$), and hypermethioninemia
41 (typically above 40 $\mu\text{mol/l}$). Thirteen Spanish, three Portuguese, one Norwegian, one
42 Indian and four Argentinian patients were included in the study. Our research was
43 conducted in accordance with the tenets of the Declaration of Helsinki. The nature
44 and possible consequences of the study were first explained to all patients and/or
45 their parents, before their informed consent for inclusion in the research project was
46 obtained.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PCR amplification and DNA sequencing

Genomic DNA was prepared from peripheral blood leukocytes, using a Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA).

All 16 *CBS* coding exons (including exon 15) and their intronic flanking regions, were amplified by PCR and sequenced as described previously (Urreizti, et al., 2006a) with some modifications. Briefly, PCR reactions were performed on a final volume of 50 μ l with 50 ng gDNA, 0.2 mM of each dNTP, 0.4 mM of each primer, 1.5–2.5 mM $MgCl_2$ and 1.25 U of GoTaq[®] Flexi DNA Polymerase (Promega, Madison, WI, USA). All mutations detected were confirmed by restriction analysis of the PCR products with the appropriate restriction enzyme, and the presence of all new mutations was assessed in 100 control chromosomes from Spanish anonymous donors. Primer sequences and PCR conditions have been described previously (Urreizti, et al., 2006a). *MTHFR* c.677C>T (rs1801133) was analyzed in all patients as described in Frosst et al. (Frosst, et al., 1995).

To characterize the deletion found in patient 87, genomic DNAs of the patient and her parents were PCR-amplified using primers 4F and 7R as described above with the addition of a final concentration of 5% DMSO. The PCR fragments were purified and sequenced.

For naming the mutations the following reference sequences were used: Genomic, GenBank NG_008938.1; cDNA, ENST00000352178. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Southern blot

A Southern blot to analyze a 36-kb fragment of the *CBS* genomic region (Fig. 1), between two *DrdI* sites, encompassing all 23 exons, plus 6 kb of the 5' flanking region and 11.5 kb of the 3' region, was performed as follows: 10 µg of patient and control gDNA were double digested by *DrdI* and *AflIII* (NEBiolabs, Ipswich, MA, USA), electrophoresed on a 0.9% agarose gel, blotted onto Amersham Hybond™-N+ (GE Healthcare, Waukesha, WI, USA) membrane using standard protocols, and fixed by UV crosslinking. The *DrdI*/*AflIII* double digestion of the 36 kb yields, in a wild-type setting, four fragments of around 15 kb, 10 kb, 8 kb and 3 kb, respectively (Fig. 1A).

Probe design, preparation and hybridization

Four probes were designed by selecting one unique sequence of approximately 600 bp within each restriction fragment. The sequences were aligned to the whole genome by BLAST, to confirm their specificity. These four sequences were PCR-amplified from total genomic DNA (as described above), cloned into pUC19 vector (Fermentas, Burlington, ON, Canada) and sequenced. Probes were obtained from the clones by using digoxigenin-dUTP and the "PCR DIG Probe Synthesis Kit" (Roche, Mannheim, Germany), according to the manufacturer's instructions. Primer sequences for the probes are available on request. Labelled probes were subsequently purified using Illustra™ GFX™ PCR DNA and a Gel Band Purification Kit (GE Healthcare, Waukesha, WI, USA).

All subsequent steps of the Southern protocol (prehybridization, hybridization and developing of the filters) were performed using reagents (Dig Easy Hyb) and protocols (Dig Application Manual) from Roche (Mannheim, Germany).

1
2
3
4
5
6 **Site-directed mutagenesis, heterologous expression and *in vitro* enzyme activity**
7
8 **assays of the *CBS* mutations**
9

10 All *CBS* mutant constructs were derived from the wild-type *CBS* expression
11 plasmid pHCS3 (Kozich and Kraus, 1992), a gift from the authors of that study. Each
12 mutation was introduced into the wild-type expression plasmid using a Quik
13 Change II XL™ Site-Directed Mutagenesis Kit (Stratagene Cloning Systems, La Jolla,
14 CA, USA) and expressed in XL-Gold *E. coli* cells as described in Urreizti et al.
15 (Urreizti, et al., 2006b). Expression of pHCS3 was used as a positive control, and that
16 of the empty vector pKK388.1 was included as a negative control. Protein extracts
17 were obtained and *CBS* activity was measured as described in Kraus (Kraus, 1987)
18 with some modifications (Urreizti, et al., 2006b).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 ***CBS* protein analysis**
36

37 To assess the presence and relative amount of wild-type and mutant *CBS*
38 proteins, Western blot analysis of the soluble fraction of the crude cell lysates was
39 performed under denaturing conditions as described in Janosik et al. (Janosik, et al.,
40 2001b), with some modifications (Urreizti, et al., 2006b).
41
42
43
44
45
46
47
48
49

50 **Minigene construction and splicing assay**
51

52 Genomic DNA from patient 68a (heterozygote for mutation c.667-14_-7del8)
53 was amplified using *CBS* primers 4F and 6R to obtain a fragment of 626 or 618 bp
54 (from the last 29 bp of intron 3 to the first 103 bp of intron 6). This PCR product,
55 containing both wild-type and mutant alleles, was purified using Illustra™ GFX™
56
57
58
59
60

1
2
3 PCR DNA and a Gel Band Purification Kit (GE Healthcare, Waukesha, WI, USA) and
4
5 cloned into the pGLB1 vector (Diaz-Font, et al., 2005). Plasmid pGLB1 is based on a
6
7 pcDNA3.1 vector and contains exons 7, 8, and 9 and introns 7 and 8 of the *GLB1*
8
9 gene, where intron 7 contains a *PmeI* restriction site, which was used to clone the *CBS*
10
11 fragment. The resulting plasmids, named pGLB1-CBS_wt and pGLB1-CBS_mut,
12
13 were confirmed by sequencing.
14
15

16
17 The splicing assay was performed by transfecting 1 μ g of each minigene
18
19 plasmid with 5 μ l of Lipofectamine 2000 Reagent (Life Technologies, Basel,
20
21 Switzerland) into 90% confluent HeLa cells. Total RNAs were isolated 24 h after
22
23 transfection using the QIAshredder and the RNeasy Mini Kit (QIAGEN, Hilden,
24
25 Germany). RNA concentration was determined spectrophotometrically, integrity was
26
27 verified by gel electrophoresis and RNA quality was assessed by OD 260/230 and
28
29 260/280 ratios.
30
31

32
33
34 Two μ g of each RNA was reverse-transcribed in a final volume of 20 μ l using a
35
36 High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied
37
38 Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
39
40

41
42 PCR amplification of each cDNA product was performed using primers T7 and
43
44 SP6 as previously described (Diaz-Font, et al., 2005; Santamaria, et al., 2008). The PCR
45
46 products were electrophoresed and each band of interest was purified and analyzed
47
48 by sequencing.
49
50

51 52 53 54 **Results**

55 56 57 **Screening for *CBS* mutations**

58
59
60

1
2
3 Twenty-two different mutations (Table 1), ten of them novel, were found in 22
4 unrelated patients of different geographical origin (Table 2). Forty-two mutant alleles
5 were identified through sequencing of coding exons and flanking intronic regions,
6 while an additional mutant allele was discovered by Southern blot analysis (see
7 below). Only one allele remained unidentified. Five of the new mutations were
8 missense while five were deletions.
9

10
11
12
13
14
15
16
17 After sequencing the complete *CBS* coding sequence, only mutation c.1566delG
18 was found in heterozygosis in patient 87, which she inherited from her father. A
19 Southern blot analysis of this patient and her mother, hybridized with a set of four
20 probes covering the entire *CBS* genomic region (Fig. 1A), revealed the same pattern
21 of bands observed in control samples but the relative intensities of fragments 2, 3 and
22 4 were altered (Fig. 1B). Hybridization of the same membrane separately with each
23 individual probe revealed an additional band of nearly 10 kb detected by probes B
24 and C (Fig. 1C). This result was consistent with a deletion removing the *DrdI* site
25 present in intron 5. To test this hypothesis, a PCR amplification from intron 3 to
26 intron 7 was performed. As shown in Fig. 1D, a new band of 1176 bp was observed in
27 the samples of the patient and her mother. Sequencing revealed a 796-bp deletion
28 (c.532-37_736+438del794), which spans from the last 37 bp of intron 4 to the first 438
29 bp of intron 6 (Fig. 1E). This deletion causes a frameshift starting from a valine to
30 glycine substitution at position 178 and leading to a stop codon at residue 201
31 (p.V178GfsX23).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 Analyses of pathogenicity of mutant *CBS* enzymes

56
57
58 None of the new mutations found was present in 100 control chromosomes,
59 ruling out the possibility of common polymorphisms.
60

1
2
3 We assessed the pathogenicity of all five new missense mutations and of the
4 novel in-frame deletion p.M173del using an *E. coli* heterologous expression system
5 followed by Western blot and *in vitro* enzyme activity analysis (Fig. 2). Mutation
6
7
8 p.P49L, previously described by de Franchis et al. (de Franchis, et al., 1998) was also
9 analyzed.

10
11
12
13
14
15 All the proteins from the mutant alleles were found in amounts similar to those
16 of the wild type (Fig. 2, upper panel). The activity of these mutant enzymes was
17 assayed *in vitro*, either in the presence or absence of the cofactor PLP, or in the joint
18 presence of PLP and SAM (Fig. 2, lower panel). As previously described (Kluijtmans,
19 et al., 1996; Maclean, et al., 2002), we found that the wild-type CBS activity was
20 strongly stimulated by both PLP and the combination of PLP and SAM. Mutations
21 p.M173del, p.I278S, p.D281N and p.D321V showed null activity, either in the absence
22 or presence of the activators. In contrast, mutations p.49L, p.P200L and p.A446S
23 retained different amounts of activity and also the ability to be stimulated.
24
25
26
27
28
29
30
31
32
33
34

35
36 In particular, mutation p.P49L displayed null activity in the absence of any of
37 the activators, retained 71% of the wild-type activity in the presence of PLP and
38 showed reduced activation by SAM. In contrast, in the absence of any of the
39 activators, mutation p.P200L displayed around a third of the activity of the wild type
40 (15% versus 43%) and retained the ability to be induced by PLP and SAM. SAM
41 stimulation was 2-fold, comparable to that of the wild type. Finally, p.A446S
42 displayed highly variable levels of activity in different tests, in the absence or
43 presence of activators, but in general the values were in the range of the wild type
44 or higher.
45
46
47
48
49
50
51
52
53
54
55

56
57
58
59
60 **Effect of a small intronic deletion on RNA splicing**

1
2
3 The small deletion c.667-14_-7del8 involved intron 5 sequences within the
4 acceptor site, without affecting the conserved AG dinucleotide. Since no RNA was
5 available from patients with this mutation (68a and 68b), a minigene assay was
6 performed to test the effect of this mutation on RNA splicing (Fig. 3A). The genomic
7 region spanning from the 3' part of intron 3 to the 5' part of intron 6 of the *CBS* gene
8 of the mutant and wild-type alleles was PCR-amplified and cloned within intron 7 of
9 a construct containing several *GLB1* exons (see Material and Methods for details).
10 Wild-type and mutant constructs were transfected into HeLa cells and splicing was
11 assayed by RT-PCR using the T7 and SP6 primers (Fig. 3B). The major band observed
12 in the wild-type sample corresponds to the inclusion of all three *CBS* exons, whereas
13 in the mutant, exon 6 was skipped, as assessed by sequencing of all the bands.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 Discussion

33
34 Mutation p.T191M was identified in 21.8% of the alleles of the Spanish and
35 Portuguese patients included in this study (Table 2). Taking into consideration all 50
36 homocystinuric patients from the Iberian Peninsula included in this and in our
37 previous studies (Urreizti, et al., 2003; 2006a), mutation p.T191M accounts for 44% of
38 the mutant chromosomes. Mutation c.1566delG is the second most prevalent change
39 (7% overall), and is particularly common in Portugal (21%). In the present study, we
40 found the panethnic mutation p.I278T for the first time in two unrelated Spanish
41 patients, both in the heterozygote state, and in a Norwegian patient, in homozygosis
42 (Table 2). Missense mutations are the most common alterations in the *CBS* gene in
43 the patients of the present study (73%). We also found six deletions of different sizes
44 (1 bp to 794 bp), five of them novel.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Southern blot analysis allowed us to identify a large deletion of nearly 800 bp in
4 the heterozygous state (c.532-37_736+438del794, p.V178GfsX23) in patient 87 and in
5 her mother. Additionally, a qmPCR assay was performed on the patient's sample
6 yielding a consistent result (C. Ged, personal communication). This patient,
7 diagnosed through neonatal screening, presented with dramatically increased
8 plasma methionine (700 μM) and total homocysteine (145 μM). She has been on a
9 normal diet and treated with pyridoxal, folate and betaine since her birth. Currently
10 aged 4 years, her plasma homocysteine and methionine levels are 76 μM and 302 μM ,
11 respectively, and she is clinically asymptomatic, highlighting the importance of an
12 early diagnosis.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 An intronic 8-bp deletion (c.667-14_-7del8) was found in two siblings (#68a-
27 #68b, Table 2). Prediction algorithms indicated a subtle reduction in the score of the
28 splicing acceptor site of intron 5. However, a mini-gene analysis clearly showed that
29 it led to the skipping of exon 6, and produced a frameshift. This is consistent with the
30 severity of the patients' phenotypes. We also found a 5 bp deletion in exon 8 in
31 patient #109, and a 1 bp deletion in exon 6 in patient #89, both in homozygosis (Table
32 2). The severity of these genotypes is in accordance with the severe clinical
33 presentation of both patients. In general, frameshift-generating deletions correlate
34 with a more consistently severe phenotype, as expected.
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Seven mutations (six missense and a 3-bp deletion) were expressed in *E. coli*
49 and analyzed by Western blot under denaturing conditions (Fig. 2, upper panel).
50 Their presence in amounts similar to those of the wild-type CBS suggests that the
51 mutations do not affect protein integrity. Alternatively, they may affect the catalytic
52 core, proper protein folding or the ability to form tetramers. In this regard, several
53 authors have studied the involvement of certain chaperones in the rescue of missense
54
55
56
57
58
59
60

1
2
3 CBS mutants, and demonstrated that the regulation of these chaperones could lead to
4 almost complete recovery of the mutant protein activity (Kopecka, et al., 2010;
5 Majtan, et al., 2010; Singh, et al., 2007; Singh, et al., 2010).
6
7
8
9

10 Four mutations showed null activity, which supports their pathogenic
11 character. These mutations, p.D281N, p.I278S, p.D321V and p.M173del, were found
12 in four unrelated patients, #82a (and his siblings), #94, #90, and #55, respectively. No
13 correlation between their null activity and the phenotypes of the patients could be
14 established since all but patient #94 presented with mild disease.
15
16
17
18
19
20
21

22 The other three mutations, displaying different degrees of enzyme activity,
23 were p.P49L, p.P200L and p.A446S, present in patients #80, #79 and #90,
24 respectively, all in the heterozygous state. In these cases, a correlation between their
25 residual activity and the mild phenotype of the patients was observed.
26
27
28
29
30
31

32 We found the activity of p.P49L to be 75% of that in the wild type. While our
33 work was ongoing, Kozich et al. (Kozich, et al., 2010) published an analysis of
34 mutation p.P49L expressed in *E. coli*. They found it to be an active enzyme,
35 indistinguishable from the wild type. Mutation p.P49L was found in two siblings,
36 one with adult onset and the other asymptomatic. Genetic analysis of the proband
37 (#80a in Table 2 and subject II.1 in Fig. 4), showed compound heterozygosity for
38 p.P49L and p.R125Q (Table 2). Genotyping of his siblings revealed an asymptomatic
39 sister also carrying both mutations (#80b; II.3 in Fig. 4). The proband had suffered a
40 myocardial infarction at age 53. Blood testing revealed moderate
41 hyperhomocysteinemia and hypermethioninemia (58 and 655 μM , respectively) and
42 he responded well to PLP (tHcy: 28 μM after treatment). On the other hand, his
43 asymptomatic sister, aged 54, presented with severe hyperhomocysteinemia (543
44 μM) and hypermethioninemia (1723 μM) but had no clinical sign of classical
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 homocystinuria and had given birth to three healthy offspring without
4 complications. As the two *CBS* mutations were inherited separately by the offspring,
5 we know that they were not in *cis* in the mother or in his affected brother. Mutation
6 p.R125Q, the other mutation in family #80, was originally described as a null activity
7 mutation (Sebastio, et al., 1995). In their recent publications, Kozich et al. (Kozich, et
8 al., 2010) and Majtan et al. (Majtan, et al., 2010) expressed it in *E. coli*. In both studies
9 the reduced activity was improved under permissive conditions or in the presence of
10 chaperones. Taken together, these new results on p.P49L and p.R125Q help explain
11 the mild or null affectation of patients #80a and #80b. In addition, the *MTHFR*
12 677C>T polymorphism may act as a phenotype modifier in this family. However, the
13 discrepancy between the blood markers and the phenotype of patient #80b remains
14 unexplained.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 Mutation p.P200L was identified as the sole mutation in patient #79. The
32 patient's symptoms are limited to hypertension and severe hyperhomocysteinemia
33 (183 μM), which does not respond to vitamin B6 and folate treatment. A second *CBS*
34 mutation may be deep intronic, located in a regulatory region far from the gene, or
35 involved in a complex rearrangement not detected by our screening methods.
36 Mutation p.A446S was found in a mildly affected patient (#90, Table 2), in compound
37 heterozygosis with the null mutation p.D321V (Fig. 2). The activity of p.A446S was
38 very similar to that of the wild type and this correlates with the mild phenotype of
39 the patient, who only presented with lens dislocation at 45 years, despite a high tHcy
40 level (105 μM , which was reduced to 40 μM after two months of treatment with folic
41 acid and vitamins B6 and B12).

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57 The poor genotype–phenotype correlation widely observed by us and others
58 among the homocystinuric patients and the demonstration that some patients
59
60

1
2
3 carrying two *CBS* mutant alleles are asymptomatic, call for environmental and
4
5 genetic modifiers involved in the pathophysiology of the disease. Some of these
6
7 genetic factors may be involved in the folding and degradation of the mutant
8
9 proteins.
10

11 12 13 14 15 16 **Acknowledgements**

17
18 The authors are grateful to the patients and their families. We also thank the
19
20 following colleagues for providing samples and clinical data: A.Baldellou and
21
22 M.T.Calvo (Zaragoza), M.T.García-Silva and M.Pardo (Madrid), M.Urtasun (San
23
24 Sebastian), O.Alonso (Huelva), A.Reparaz and C.Torreira (Vigo), I.C.Verma (New
25
26 Delhi, India). **Robin Rycroft revised the English.** The CIBER de Enfermedades Raras
27
28 (CIBERER) is an initiative of the ISCIII. This study was supported by grants from
29
30 Ministerio de Ciencia e Innovación (Grants SAF2007-64654; SAF2010-15707;
31
32 PIB2010AR-00473), and the Catalan Department of Universities, Research and the
33
34 Information Society (2005SGR 00848, 2009 SGR 971).
35
36
37
38

39 40 **References:**

- 41
42 Banerjee R, Zou C. 2005. Redox regulation and reaction mechanism of human cystathionine-
43
44 β -synthase: a PLP-dependent hemesensor protein. *Arch Biochem Biophys* 433:144-
45
46 156.
47 Bukovska G, Kery V, Kraus JP. 1994. Expression of human cystathionine beta-synthase in
48
49 *Escherichia coli*: purification and characterization. *Protein Expr Purif* 5:442-8.
50
51 Chen X, Wang L, Fazlieva R, Kruger WD. 2006. Contrasting behaviors of mutant
52
53 cystathionine beta-synthase enzymes associated with pyridoxine response. *Hum Mutat*
54
55 27:474-82.
56
57 de Franchis R, Kozich V, McInnes RR, Kraus JP. 1994. Identical genotypes in siblings with
58
59 different homocystinuric phenotypes: identification of three mutations in cystathionine
60
B-synthase using an improved bacterial expression system. *Hum Mol Genet* 3:1103-
1108.
de Franchis R, Sperandio MP, Sebastio G, Andria G. 1998. Clinical aspects of cystathionine
beta-synthase deficiency: how wide is the spectrum? The Italian Collaborative Study
Group on Homocystinuria. *Eur J Pediatr* 157 Suppl 2:S67-70.
Diaz-Font A, Santamaria R, Cozar M, Blanco M, Chamoles N, Coll MJ, Chabas A, Vilageliu
L, Grinberg D. 2005. Clinical and mutational characterization of three patients with

- multiple sulfatase deficiency: report of a new splicing mutation. *Mol Genet Metab* 86:206-11.
- El-Said MF, Badii R, Bessisso MS, Shahbek N, El-Ali MG, El-Marikhie M, El-Zyoid M, Salem MS, Bener A, Hoffmann GF and others. 2006. A common mutation in the CBS gene explains a high incidence of homocystinuria in the Qatari population. *Hum Mutat* 27:719.
- Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den HM, Kluijtmans LA, van dHL and others. 1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. *Nat Genet* 10:111-3.
- Gallagher PM, Ward P, Tan S, Naughten E, Kraus JP, Sellar GC, McConnell DJ, Graham I, Whitehead AS. 1995. High frequency (71%) of Cystathionine B-Synthase Mutation G307S in Irish Homocystinuria Patients. *Hum Mutat* 6:177-180.
- Gaustadnes M, Ingerslev J, Rutiger N. 1999. Prevalence of congenital homocystinuria in Denmark. *N Engl J Med* 340:1513.
- Janosik M, Meier M, Kery V, Oliveriusova J, Burkhard P, Kraus JP. 2001a. Crystallization and preliminary X-ray diffraction analysis of the active core of human recombinant cystathionine beta-synthase: an enzyme involved in vascular disease. *Acta Crystallogr D Biol Crystallogr* 57:289-91.
- Janosik M, Oliveriusova J, Janosikova B, Sokolova J, Kraus E, Kraus JP, Kozich V. 2001b. Impaired heme binding and aggregation of mutant cystathionine beta-synthase subunits in homocystinuria. *Am J Hum Genet* 68:1506-1513.
- Kabil O, Toaka S, LoBrutto R, Shoemaker R, Banerjee R. 2001. Pyridoxal phosphate binding sites are similar in human heme-dependent and yeast heme-independent cystathionine beta-synthases. Evidence from ³¹P NMR and pulsed EPR spectroscopy that heme and PLP cofactors are not proximal in the human enzyme. *J Biol Chem* 276:19350-5.
- Katsushima F, Oliveriusova J, Sakamoto O, Ohura T, Kondo Y, Iinuma K, Kraus E, Stouracova R, Kraus JP. 2006. Expression study of mutant cystathionine beta-synthase found in Japanese patients with homocystinuria. *Mol Genet Metab* 87:323-8.
- Kery V, Poneleit L, Meyer JD, Manning MC, Kraus JP. 1999. Binding of pyridoxal 5-phosphate to the heme protein human cystathionine beta-synthase. *Biochemistry* 38:2716-2724.
- Kluijtmans LA, Boers GH, Stevens EM, Renier WO, Kraus JP, Trijbels FJ, van den Heuvel LPWJ, Blom HJ. 1996. Defective Cystathionine B-synthase regulation by S-Adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. *J Clin Invest* 98:285-289.
- Kopecka J, Krijt J, Rakova K, Kozich V. 2011. Restoring assembly and activity of cystathionine beta-synthase mutants by ligands and chemical chaperones. *J Inherit Metab Dis*. 34:39-48.
- Kozich V, Kraus JP. 1992. Screening for mutations by expressing patient cDNA segments in *E. coli*: Homocystinuria due to Cystathionine β -Synthase Deficiency. *Hum Mutat* 1:113-123.
- Kozich V, Sokolova J, Klatovska V, Krijt J, Janosik M, Jelinek K, Kraus JP. 2010. Cystathionine beta-synthase mutations: effect of mutation topology on folding and activity. *Hum Mutat* 31:809-19.
- Kraus J. 1987. Cystathionine b-synthase. *Methods in enzymology* 143:388-394.
- Kraus J, Janosik M, Kozich V, Mandell R, Shih V, Sperandeo MP, Sebastio G, de Franchis R, Andria G, Kluijtmans LAJ and others. 1999. Cystathionine beta-synthase mutations in homocystinuria. *Hum Mutat* 13:362-375.

- 1
2
3 Maclean KN, Gaustadnes M, Oliveriusova J, Janosik M, Kraus E, Kozich V, Kery V, Skovby
4 F, Rudiger N, Ingerslev J and others. 2002. High homocysteine and thrombosis
5 without connective tissue disorders are associated with a novel class of cystathionine
6 beta-synthase (CBS) mutations. *Hum Mutat* 19:641-655.
- 7
8 **Magner M, Krupkova L, Honzik T, Zeman J, Hyanek J, Kozich V. 2011. Vascular**
9 **presentation of cystathionine beta-synthase deficiency in adulthood. *J Inherit Metab***
10 ***Dis* 34:33-7.**
- 11 Majtan T, Liu L, Carpenter JF, Kraus JP. 2010. Rescue of cystathionine beta-synthase (CBS)
12 mutants with chemical chaperones: purification and characterization of eight CBS
13 mutant enzymes. *J Biol Chem.* 285:15866-15873.
- 14 Meier M, Janosik M, Kery V, Kraus JP, Burkhard P. 2001. Structure of human cystathionine
15 beta-synthase: a unique pyridoxal 5'-phosphate-dependent heme protein. *EMBO J*
16 20:3910-3916.
- 17
18 Moat SJ, Bao L, Fowler B, Bonham JR, Walter JH, Kraus JP. 2004. The molecular basis of
19 cystathionine beta-synthase (CBS) deficiency in UK and US patients with
20 homocystinuria. *Hum Mutat* 23:206.
- 21
22 Mudd S, Levy H, Tangerman A, Boujet C BN, Davidson-Mundt A, Hudgins L, Oyanagi K,
23 Nagao M, Wilson W. 1995. Isolated persistent hypermethioninemia. *Am J Hum Genet*
24 57:882-92.
- 25
26 Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GH,
27 Bromberg IL, Cerone R and others. 1985. The natural history of homocystinuria due
28 to cystathionine beta-synthase deficiency. *Am J Hum Genet* 37:1-31.
- 29 **Refsum H, Fredriksen A, Meyer K, Ueland PM, Kase BF. 2004. Birth prevalence of**
30 **homocystinuria. *J Paediatr* 144:830-832.**
- 31
32 Santamaria R, Vilageliu L, Grinberg D. 2008. SR proteins and the nonsense-mediated decay
33 mechanism are involved in human GLB1 gene alternative splicing. *BMC Res Notes*
34 1:137.
- 35
36 Sebastio G, Sperandeo MP, Panico M, de Franchis R, Kraus JP, Andria G. 1995. The
37 molecular basis of homocystinuria due to Cystathionina B-Synthasa deficiency in
38 italian families, and report of four novel mutations. *Am J Hum Genet* 56:1324-1333.
- 39
40 Singh LR, Chen X, Kozich V, Kruger WD. 2007. Chemical chaperone rescue of mutant
41 human cystathionine beta-synthase. *Mol Genet Metab* 91:335-42.
- 42
43 Singh LR, Gupta S, Honig NH, Kraus JP, Kruger WD. 2010. Activation of mutant enzyme
44 function in vivo by proteasome inhibitors and treatments that induce Hsp70. *PLoS*
45 *Genet* 6:e1000807.
- 46
47 Skovby F, Gaustadnes M, Mudd SH. 2010. A revisit to the natural history of homocystinuria
48 due to cystathionine beta-synthase deficiency. *Mol Genet Metab* 99:1-3.
- 49
50 Taoka S, Lepore BW, Kabil O, Ojha S, Ringe D, Banerjee R. 2002. Human cystathionine
51 beta-synthase is a heme sensor protein. evidence that the redox sensor is heme and not
52 the vicinal cysteines in the CXXC motif seen in the crystal structure of the truncated
53 enzyme. *Biochemistry* 41:10454-10461.
- 54
55 Urreizti R, Asteggiano C, Bermudez M, Cordoba A, Szlago M, Grosso C, de Kremer RD,
56 Vilarinho L, D'Almeida V, Martinez-Pardo M and others. 2006a. The p.T191M
57 mutation of the CBS gene is highly prevalent among homocystinuric patients from
58 Spain, Portugal and South America. *J Hum Genet* 51:305-13.
- 59
60 Urreizti R, Asteggiano C, Cozar M, Frank N, Vilaseca MA, Grinberg D, Balcells S. 2006b.
Functional assays testing pathogenicity of 14 cystathionine-beta synthase mutations.
Hum Mutat 27:211.
- Urreizti R, Balcells S, Rodes M, Vilarinho L, Baldellou A, Couce ML, Munoz C, Campistol
J, Pinto X, Vilaseca MA and others. 2003. Spectrum of CBS mutations in 16

- 1
2
3 homocystinuric patients from the Iberian Peninsula: high prevalence of T191M and
4 absence of I278T or G307S. *Hum Mutat* 22:103.
- 5 Walter JH, Wraith JE, White FJ, Bridge C, Till J. 1998. Strategies for the treatment of
6 cystathionine beta-synthase deficiency: the experience of the Willink Biochemical
7 Genetics Unit over the past 30 years. *Eur J Pediatr* 157 Suppl 2:S71-6.
- 8 Wilcken DE, Wilcken B. 1997. The natural history of vascular disease in homocystinuria and
9 the effects of treatment. *J Inherit Metab Dis* 20:295-300.
- 10 Yap S, Boers GHJ, Wilcken B, Wilcken DEL, Brenton DP, Lee PJ, Walter JH, Howard PM,
11 Naughten ER. 2001. Vascular outcome in patients with homocystinuria due to
12 cystathionine beta-synthase deficiency treated chronically - A multicenter
13 observational study. *Arterioscl Thromb Vas Biol* 21:2080-2085.
- 14 Yap S, Naughten E. 1998. Homocystinuria due to cystathionine beta-synthase deficiency in
15 Ireland: 25 years' experience of a newborn screened and treated population with
16 reference to clinical outcome and biochemical control. *J Inherited Metab Dis* 21:738-
17 747.
- 18
19
20
21
22
23
24
25
26

27 Figure Legends:

28
29 **Figure 1.** Southern Blot analysis of the *CBS* gene. **A:** scheme of the human *CBS* gene.
30 The *DrdI* (D) and *AflIII* (A) restriction sites and the corresponding restriction
31 fragments (F1 to F4) are indicated below the scheme. The positions of the probes (A
32 to D) are indicated above. **B:** Southern Blot analysis of patient #87 and her mother
33 (#87m) hybridized with the whole set of probes. Two wild-type DNAs were included
34 in the analysis. M: Molecular weight marker. **C:** Southern Blot analysis hybridized
35 with probe B. The arrow indicates the new band found in the patient and her mother.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **Figure 2.** Heterologous expression and activity of seven *CBS* mutations. **A:** SDS-
59 PAGE followed by Western blot immunodetection of wild-type and mutant *CBS*
60

1
2
3 proteins expressed in *E. coli* XL Gold. Ten μg of total protein extract was loaded in
4 each lane. Six replicates were performed for each mutation. pKK: Empty vector used
5 as negative control. **B:** *In vitro* enzyme activity of wild-type and mutant *CBS* alleles
6 from *E. coli* XL Gold extracts in the absence of both PLP and SAM (black boxes), in
7 the presence of PLP (grey boxes), and in the presence of both PLP and SAM (white
8 boxes). Wild-type *CBS* activity in the presence of PLP was taken as the reference
9 value (100%). Activity values greater than 4% are indicated in the figure. Values are
10 the means of six replicates. Error bars represent SD.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 **Figure 3.** Splicing analysis of mutation c.667-14_-7del8 included in a minigene
26 construction. **A:** scheme of the minigene: grey boxes represent *GLB1* exons and white
27 boxes are *CBS* exons. The thick horizontal line represents the *CBS* introns and the
28 thin line the *GLB1* introns. PCMV: CMV promoter; BGHpA: BGH polyadenylation
29 site. Wild-type and mutant splicing patterns are indicated above and below the gene
30 respectively. The dot indicates the position of the mutation. The wild-type and
31 mutant constructs were transiently transfected into HeLa cells. Total RNA was
32 extracted 24 h after transfection, reverse-transcribed and PCR-amplified with primers
33 T7 and SP6 (indicated by arrows). **B:** PCR amplification of the wild-type (1) mutant
34 (2) and the minigene construct without the *CBS* exons (3). The asterisk points to a
35 minor band lacking exon 4 observed in the wild-type construct. **C:** Diagrams
36 showing the three main PCR products.

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 **Figure 4.** Pedigree of family 80. Patient 80a (II.1), the proband, is marked with an
53 arrow. Patient 80b is member II.3. *CBS* genotypes are indicated below the pedigree
54 symbols; the *MTHFR* c.677C>T genotypes are also included in brackets. Total plasma
55 homocysteine levels ($\mu\text{Mol/L}$) are indicated when available. NA: not available.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table 1. List Of The 22 Different Mutations Found In This Cohort.

DNA	Deduced Protein Change	Exon-Intron	Alleles	Restr. Enz. ¹	References
c.146C>T	p.P49L	Ex 1	1		de Franchis et al., 1998
c.253G>A	p.G85R	Ex 2	1		Maclean et al., 2002
c.361C>T	p.R121C	Ex 3	1		Katsushima et al., 2006
c.374G>A	p.R125Q	Ex 3	1		Marble et al., 1994
c.518delTGA	p.M173del	Ex 4	2		This study
c.532-37_736+438del794	p.V178GfsX23	In 4-In 6	1		This study
c.572C>T	p.T191M	Ex 5	7		Urreizti et al., 2003
c.599C>T	p.P200L	Ex 5	1	MspI-	This study
c.667-14_667-7del8	p.Y223GfsX23	In 5	1		This study
c.676G>A	p.A226T	Ex 6	2		Shan et al., 1998
c.689delT	p.L230RfsX39	Ex 6	1	MspI+	This study
c.824G>A	p.C275Y	Ex 7	1		Urreizti et al., 2003
c.833T>G	p.I278S	Ex 8	1	TspRI+	This study
c.833T>C	p.I278T	Ex 8	4		Kozich et al., 1992
c.841C>T	p.D281N	Ex 8	1	BamHI-	This study
c.862_866del5	p.E289GfsX39	Ex 8	2		This study
c.962A>T	p.D321V	Ex 9	1	Hpy8I-	This study
c.1085C>T	p.T353M	Ex 10	2		Dawson et al., 1997
c.1136G>A	p.R379Q	Ex 10	1		Urreizti et al., 2003
c.1330G>A	p.D444N	Ex 12	4		Kluijtmans et al., 1996
c.1336G>T	p.A446S	Ex 12	1	BstNI+	This study
c.1566delG	p.K523SfsX18	Ex 16	5		Castro et al., 1999

Mutations not previously described are indicated in bold

¹Novel missense mutations were checked in control chromosomes using the indicated enzyme. +: the mutation creates a new site; -: the mutation destroys a site.

Reference Sequences: Genomic, GenBank NG_008938.1; cDNA, ENST00000352178. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.


Table 2. Patients, CBS And MTHFR C.667C>T Genotypes, Disease Severity And Geographical Origin

Patient	Genotype	MTHFR (c.677 C>T)	Severity	Country
74	p.[T353M]+[D444N]	TT	Severe	Spain
79	p.[P200L]+[?]	CT	Asymptomatic	Spain
80a	p.[R125Q]+[P49L]	TT	Mild	Spain
80b	p.[R125Q]+[P49L]	CT	Asymptomatic	
82a	p.[T191M]+[D281N]	CC	Mild	Spain
82b	p.[T191M]+[D281N]	CC	Mild	
82c	p.[T191M]+[D281N]	CC	Mild	
83	p.[T353M]+[D444N]	TT	Mild	Spain
84	p.[I278T]+[R121C]	CT	Mild	Spain
88	p.[D444N]+[D444N]	CT	Mild	Spain
92	p.[T191M]+[T191M]	CT	Mild	Spain
93	p.[T191M]+[T191M]	CT	Severe	Spain
94	p.[T191M]+[I278S]	CT	Severe	Spain
100	p.[T191M]+[R379Q]	CT	Mild	Spain
107	c.[1566delG]+[1566delG]	CT	NA	Spain
108	p.[I278T]+[C275Y]	TT	Mild	Spain
81	c.[1566delG]+[1566delG]	TT	Severe	Portugal
87	c.[1566delG]+[532-37_736+438del794]	CC	neonatal screening (asymptomatic)	Portugal
109	p.[E289GfsX39]+[E289GfsX39]	CT	Severe	Portugal
68a	p.[G85R]+c.[667-14_667-7del8]	CT	Severe	Argentina
68b	p.[G85R]+c.[667-14_667-7del8]	CT	Severe	
89	c.[689delT]+[689delT]	CT	Severe	Argentina
90	p.[D321V]+[A446S]	CT	Mild	Argentina
91	p.[A226T]+[A226T]	CT	Severe	Argentina
105	p.[I278T]+[I278T]	ND	NA	Norway
55	p.[M173del]+[M173del]	ND	Mild	Indian

ND: Not Determined.

NA: Not Available.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



355x266mm (72 x 72 DPI)

Review


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



355x266mm (72 x 72 DPI)

Review


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



355x266mm (72 x 72 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



355x266mm (72 x 72 DPI)

Review